Kymera Therapeutics (KYMR) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

KYMR · Stock Price

USD 84.63+54.56 (+181.44%)

Market Cap: $7.0B

Historical price data

Market Cap: $7.0BPipeline: 9 drugsPatents: 20Founded: 2016Employees: 200-500HQ: Watertown, United States

Sector Ranking#114 in Small Molecule Drugs #4 in Proteomics & Protein Engineering

Overview

Kymera Therapeutics is a leader in the targeted protein degradation field, translating its innovative Pegasus™ platform into a robust clinical pipeline. The company has achieved significant validation through positive early clinical data for its lead programs, KT-621 and KT-333, demonstrating proof-of-concept for its oral degraders. Kymera's strategy is to build a fully integrated biopharmaceutical company by advancing its wholly-owned assets while selectively leveraging strategic partnerships to expand its reach and capabilities.

ImmunologyOncologyAutoimmune

Technology Platform

The Pegasus™ platform is an integrated drug discovery engine for designing oral, heterobifunctional small molecule degraders (PROTACs), combining computational chemistry, structural biology, proteomics, and medicinal chemistry to target previously undruggable proteins.

Pipeline

9

9 drugs in pipeline

Drug	Indication	Stage
KT-621	Eosinophilic Asthma	Phase 2
KT-621	Atopic Dermatitis	Phase 2
KT-621	Atopic Dermatitis	Phase 1
KT-413	Non Hodgkin Lymphoma	Phase 1
KT-474/Placebo + KT-474	Healthy Volunteer	Phase 1

Funding History

4

Total raised:$371.6M

IPO$173.6MUndisclosedAug 13, 2020

Series C$102MWellington ManagementJul 15, 2020

Series B$65MBessemer Venture PartnersJan 15, 2019

Series A$31MAtlas VentureOct 15, 2017

Opportunities

Kymera's lead oral STAT6 degrader, KT-621, addresses a multi-billion dollar atopic dermatitis market ripe for an oral best-in-class therapy.

The broader targeted protein degradation field represents a paradigm shift with the potential to unlock ~80% of the human proteome, creating a long-term pipeline engine.

Risk Factors

Key risks include clinical failure in late-stage trials for lead assets, intense competition from established biologics and other novel modalities in immunology/oncology, and the inherent technological risks associated with the long-term safety and manufacturability of a pioneering protein degradation platform.

Competitive Landscape

Kymera competes with other TPD leaders like Arvinas (oncology) and Nurix Therapeutics, as well as large pharma companies building internal capabilities. Its key advantages are a focus on oral bioavailability for chronic diseases, strong early clinical data, and a validated platform through its Sanofi partnership.